Results 71 to 80 of about 5,449 (190)

Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers [PDF]

Background: Cefiderocol may potentially be used to treat skin and soft tissue infections (SSTIs). However, the pharmacokinetics of cefiderocol in human soft tissues have not yet been determined.
Coen van Hasselt, J. G., Bergmann, Felix, Minichmayr, Iris K., Lackner, Edith, van Os, Wisse, Zeitlinger, Markus, Dorn, Christoph, Pham, Anh Duc, Lier, Constantin, Sanz-Codina, Maria, al Jalali, Valentin, Jorda, Anselm, Wölf-Duchek, Michael   +12 more
core   +1 more source

Optimisation of a Novel Class of DNA Gyrase Inhibitors to Improve Antibacterial Activity

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
This article describes efforts to increase the antibacterial activity of a recently reported class of novel DNA gyrase inhibitors known as the isoquinoline sulphonamides by improving their uptake in bacterial cells. As antibiotic resistance continues to rise, the need for new antibacterials is clear.
Meg I. Ferguson, Cerissa C. van Walstijn, Vladyslav Lysenko, Marta A. Wilbrink, David Alencar Araripe, Jeroen M. Punt, Mario van der Stelt, Willem Jespers, Paolo Innocenti, Nathaniel I. Martin   +9 more
wiley   +1 more source

Functional dynamics of water in New Delhi metallo‐β‐lactamase catalysis

Protein Science, Volume 35, Issue 6, June 2026.
Abstract Water plays a critical role in the hydrolysis of antibiotics by New Delhi metallo‐β‐lactamases (NDMs). The reaction proceeds through a nucleophilic attack on the β‐lactam ring, followed by cleavage of the C–N bond and formation of an anionic nitrogen intermediate. This intermediate is then protonated by a water molecule diffusing from the bulk
Palanisamy Kandhan, Chuanye Xiong, Timothy Palzkill, Peng Tao   +3 more
wiley   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

World Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock, Timothy C. Hardcastle, Christine Gaarder, Amit Gupta, Adam Gyedu, Manjul Joshipura, Elmin Steyn, on behalf of the Essential Trauma Care revision author group, Valencia Adjei, Roger Alcock, Vanda Amado, Michael Boampong, Sanjeev Booi, Petra Brysiewicz, Corazon Cabanilla‐Manuntag, Cristiane de Alencar Domingues, Ghada Elhadari, Ranjith Nanda Ellawala, Sarnai Erdene, Ama Akoma Essuman, Jorge Esteban Foianini, Filippo Gatti, Armando Garcia Guererra, Greg Hynes, Adil Haider, Sandy Ingless, Balavenkata Jagannathan, Helen Jowett, Knut Magne Kolstadbråten, Sonja Krofak, Aireen Patricia Madrid, Tina Tomić Mahečić, Claude Martin, Daniel Ntogwrachu, Bisola Onajin‐Obembe, Nhobojit Roy, Andres Rubiano, Niisoja Mensah Torto, Ben Wachira, Meg Walmsley, Torben Wisborg, Elma Wong   +41 more
wiley   +1 more source

Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study [PDF]

Cornelius J Clancy,1 Oliver A Cornely,2– 4 Stephen W Marcella,5 Sean T Nguyen,6 Laurence Gozalo,7 Bin Cai8 1Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Institute of Translational Research, Cologne Excellence Cluster on ...
Cai B, Cornely OA, Nguyen ST, Marcella SW, Gozalo L, Clancy CJ   +5 more
core  

In vitro activity of cefiderocol against nosocomial Acinetobacter baumannii

Microbiology Spectrum
The emergence and spread of third-/fourth-generation cephalosporin and/or carbapenem-resistant Acinetobacter baumannii have become a significant global public health concern, making new treatment alternatives necessary.
Barbara Ymaña, Rocío Egoávil-Espejo, Rosario Huerto-Huánuco, Rosario Oporto-Llerena, Carla A. Alonso, Angie K. Castillo, Luciano A. Palomino-Kobayashi, Carmen Valera-Krumdieck, Gabriela Soza, Tamin Ortiz-Gomez, Patricia Gonzales, María López, Gina Salvador-Luján, Beatriz Rojo-Bezares, Martin Casapia, Paula Toledano, Joseph Pinto, Maria Ramos Chirinos, Yolanda Sáenz, Maria J. Pons, Joaquim Ruiz   +20 more
doaj   +1 more source

Kineochelins—A New Group of Siderophores From an Antarctic Bacterium

Microbial Biotechnology, Volume 19, Issue 6, June 2026.
Genome‐guided analysis of an Antarctic Actinokineospora strain led to the discovery of kineochelins, a new group of siderophores involved in iron sequestration and microbial competition. Kineochelin production inhibits co‐occurring bacteria and clinically relevant yeasts, highlighting Antarctic microorganisms as promising sources of bioactive natural ...
Stanislava Kralova, Peter Spacek, Johannes Gafriller, Matej Bezdicek, Viktoria Medvedcova, Joana Séneca, Jay Osvatic, Ulrike Grienke, Thomas Rattei, Olga N. Sekurova, Sergey B. Zotchev, Martin Zehl, Alexander Loy   +12 more
wiley   +1 more source

Efficacy of Cefiderocol Against Endophthalmitis Isolates

Background/Objectives: Endophthalmitis is an intraocular microbial infection that can lead to permanent blindness, even with prompt anti-microbial therapy.
Jonathan B. Mandell, Eric G. Romanowski, Brennan Schilling, Hazel Q. Shanks, Robert M. Q. Shanks, Michael Hii, Michael Zegans   +6 more
core   +1 more source

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

Microbiology Spectrum
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough, Maura H. Karr, Sean T. Nguyen, Boudewijn L. M. DeJonge, Chris Longshaw, Miki Takemura, Yoshinori Yamano, Mariana Castanheira, Rodrigo E. Mendes   +8 more
doaj   +1 more source

Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections

Background: Cefiderocol exhibits potent in vitro activity against carbapenem-resistant Acinetobacter baumannii (CRAb), but this activity has not consistently translated to improved outcomes among patients. Cefiderocol heteroresistance, or the presence of
Griffith, Marissa P, Tiseo, Giusy, Barnini, Simona, Shields, Ryan K, Giordano, Cesira, Dorazio, Ava J, Squires, Kevin M, Doi, Yohei, Leonildi, Alessandro, Van Tyne, Daria, Kline, Ellen G, Falcone, Marco, Iovleva, Alina   +12 more
core   +1 more source